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Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on 
the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer 
hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previ-
ously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) 
patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, 
but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. 
Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, simi-
larly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control 
hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic 
kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main 
contributor to increased mortality in the HD population because of cardiovascular calciﬁ  ca-
tion, metabolic acidosis has also been advocated as a major player in the increased mortality 
in this population, by engendering malnutrition, negative nitrogen balance, and inﬂ  ammation. 
This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer 
hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in 
serum bicarbonate balance.
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Introduction
Chronic kidney disease (CKD) has become a major worldwide healthcare problem, 
affecting an estimated 5%–10% of the world’s population (Hamer and El Nahas 
2006). Progression to end stage renal disease (ERSD), the need for renal replacement 
therapy, and the high annual death rate of dialysis patients are the most noticeable 
outcomes of CKD. Most patients with CKD in fact die mainly from cardiovascular 
disease, rather than from ERSD. Coronary artery calciﬁ  cation (CAC), a surrogate 
marker of atherosclerosis, is a common ﬁ  nding in CKD. Extensive calciﬁ  cation has 
been documented in dialysis patients by computed tomography, but cardiovascular 
calciﬁ  cation (CVC) affects patients not undergoing dialysis as well, developing early 
in the progression of CKD, and progressively worsening with the decline of the glo-
merular ﬁ  ltration rate (GFR), particularly in diabetics progressing to ERSD (Qunibi 
2007). Presence of proteinuria, reduced renal function, diabetic nephropathy, and the 
progression rate to ERSD are the classical main uremia-related factors that increase 
the risk of calciﬁ  cation in CKD. Several observational studies have now identiﬁ  ed the 
altered mineral metabolism, and particularly hyperphosphatemia, as a key player in 
CVC and not exclusively in musculoskeletal health. Hyperphosphatemia associated 
with surrogate clinical events such as CAC, aortic calciﬁ  cation, valvular calciﬁ  ca-
tion, aortic stiffness, pulse pressure, as well as with hard clinical outcomes such as Therapeutics and Clinical Risk Management 2008:4(4) 822
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hospitalization, and all-cause and cardiovascular mortality 
(Young et al 2005; Young 2007; Toussaint and Kerr 2007). 
Elevated serum phosphorus (P) level is highly prevalent in 
uremic patients, despite diet restriction and dialysis. It is 
associated with an increased mortality risk in hemodialysis 
(HD) patients. Block et al (1998), through a multivariate 
analysis of data from the United States Renal Data System 
(URDS), identiﬁ  ed elevated serum P level as an independent 
predictor of mortality. The overall mortality risk associated 
with serum P above 6.5 mg/dL was 27% greater than that of 
patients with serum P between 2.4 and 6.5 mg/dL. Moreover, 
Ca × P product greater than 72 mg2/dL2 was also associated 
with increased mortality risk. Altered mineral metabolism 
could aggravate the effects of coronary atherosclerosis. An 
increased intracellular P intake via Pit-1, a sodium-dependent 
P co-transporter, stimulates the phenotypic conversion of 
smooth muscle cell to osteoblatic cell lineage, thus leading to 
an increased extracellular matrix deposition favoring Ca × P 
product precipitation, with the proposed ﬁ  nal outcome of 
vascular stiffness (Giachelli 2003; Li et al 2006). In primary 
cultures of vascular smooth muscle cells derived from ath-
erosclerotic human aortas, activation of osteoblast speciﬁ  c 
transcriptional programs related to skeletal morphogenesis 
did not lead to matrix mineralization until the P concentration 
of the tunica media was increased, an event occurring only 
after the onset of renal dysfunction and hyperphosphatemia 
(Mathew et al 2008). Indeed, using high-resolution B-mode 
ultrasonography, Kawagishi et al (1995) found that elevated 
serum P level was strongly associated with changes in intima-
media thickness of the carotid artery, an effect independent 
of several other commonly measured coronary risk factors. It 
was therefore hypothesized that the increased mortality risk 
associated with elevated P level in HD patients was primarily 
due to cardiac rather than non-cardiac causes of death. In a 
chronic HD patients with serum P > 6.5 mg/dL, Ganesh et al 
(2001) demonstrated a 41% greater risk of death resulting 
from coronary artery disease (CAD) and a 20% greater risk 
of death resulting from sudden death compared with patients 
with serum P level between 2.4 and 6.5 mg/dL. Comparing 
death risk between CAD and non-CAD causes of death in 
HD patients, he showed that elevated serum P level in HD 
patients signiﬁ  cantly and preferentially predisposes to CAD 
deaths, thus supporting the concept of hyperphosphatemia 
as a cardiotoxin. The author suggested a role for elevated 
serum P either in the development, progression, or rupture 
of atheromatous plaques in the coronary arteries of preva-
lent ERSD patients. All the previous analysis involved HD 
populations with serum P > 6.5 mg/dL, which means a 
P value at least 1 mg/dL higher than the National Kidney 
Foundation (K/DOQI) recommended upper limit of 5.5 mg/
dL for chronic HD patients. Interestingly, both in CKD 
patients with serum P within the K/DOQI recommended 
serum P level range (>2.7 and <4.5 mg/dL), as in the case of 
stage 3 CKD patients (Kestenbaum et al 2005), and in stage 
4 CKD patients with elevated serum P but not yet in dialy-
sis, arterial stiffness and mortality risk from cardiovascular 
events are signiﬁ  cantly increased (Sigrist et al 2007).
Hyperphosphatemia and phosphate 
binders
The evidence that links mortality with altered mineral 
metabolism, and particularly the association of mortality 
with elevated serum P and Ca × P levels, is well documented. 
Therefore, mineral metabolism provides a new perspective 
for improving mortality in patients with kidney disease. 
Hyperphosphatemia requires strict management through 
dietary restriction, dialysis, and use of phosphate binders. 
Phosphate binder therapy is a critical factor in the manage-
ment of hyperphosphatemia in advanced kidney disease. The 
aim is to achieve serum P  5.5 mg/dL in HD patients, and 
possibly even lower. Phosphate binders mainly act in reduc-
ing the amount of bioavailable PO4 generated by food intake 
into gastrointestinal ﬂ  uids, through precipitation and/or 
entrapment, and potentiating its excretion by the fecal route. 
Several options are commercially available, namely: calcium 
carbonate and calcium acetate, magnesium hydroxide and 
magnesium carbonate, aluminium hydroxide, lanthanum 
carbonate, the non-calcium and metal-free sevelamer 
hydrochloride (for review: Almirall and Valenzuela 
2006; Cozzolino et al 2008), and sevelamer carbonate 
(Renvela®   which obtained FDA approval in October 2007, 
but is not approved yet in EU). Others substances are cur-
rently under development (McIntyre 2007). It is beyond the 
aim of this review to provide details on all the above-listed 
phosphate binders. Nevertheless, it is worth noting that each 
of those listed, although to various degrees effective in serum 
P reduction, is not devoid of concern (for review: Almirall 
and Valenzuela 2006). Systemic toxicity, observed as liver, 
lung, and kidney deposition, and neurotoxicity, has been 
reported for lanthanum carbonate at the experimental level 
(Lacour et al 2005, 2007; Slatopolsky et al 2005), but not 
yet in the clinical setting (Cozzolino et al 2008), and some 
criticism remains because of past experience with another 
metal-based P binder, aluminium hydroxide (Drüeke 2007). 
An increase in vascular calciﬁ  cation, suggestive of a possibly 
increased mortality risk, has been advocated for calcium-based Therapeutics and Clinical Risk Management 2008:4(4) 823
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PO4 binders. Intolerance to sevelamer in 9%–34% of HD 
patients because of gastrointestinal complaints (Almirall 
and Valenzuela 2006), worsening of metabolic acidosis (De 
Santo et al 2006), reports of stercoral ulceration (Madan et al 
2008), and peritonitis (EMEA 2007) have been highlighted 
for sevelamer hydrochloride. The Dialysis Outcomes and 
Practice Patterns Study (DOPPS) revealed considerable varia-
tion in the use of phosphate binders among the seven different 
countries participating in the study, although calcium-based 
binders were the preferred option (Young et al 2005). At that 
time, the use of non-calcium and metal-free polymers such 
as sevelamer was clearly underestimated because of the very 
recent approval of the pharmaceutical. Nowadays, unexpect-
edly, most patients are still prescribed calcium-based agents, 
despite evidence of increased vascular calciﬁ  cation, arterial 
stiffness, and coronary calciﬁ  cation both in HD and predialy-
sis patients (Block et al 2007; Russo et al 2007; Sigrist et al 
2007). The widespread use of calcium-based binders could 
have several explanations. Some authors have reported that 
calcium-based salts in HD patients showed good phosphate-
binding capability, cost affordability, and lack of compel-
ling evidence for a signiﬁ  cantly reduced outcome in overall 
mortality compared with sevelamer (St. Peter et al 2008; 
Suki 2008). Others, however, have interpreted the reduced 
calciﬁ  cation in sevelamer-treated patients by its lipid-lower-
ing properties more than its phosphate-binding properties 
(Winkelmayer and Tonelli 2008).
Sevelamer carbonate in HD 
patients
Sevelamer carbonate is an anion exchange pharmaceutical, 
recently developed as an improvement of the non-absorbable 
sevelamer hydrochloride. It was developed to avoid wors-
ening of metabolic acidosis, reported as one of the possible 
concerning side effects of sevelamer hydrochloride long-term 
treatment, and to increase patients’ compliance through the 
development of new pharmaceutical presentation (Duggal 
et al 2006). Sevelamer hydrochloride is a non-calcium and 
non-metal quaternary amine anion exchange resin, which 
upon binding to a PO4 molecule by ionic and/or hydrogen 
bonding releases one hydrochloride molecule. For this 
reason, sevelamer hydrochloride has been demonstrated 
to worsen the metabolic acidosis that affects HD patients, 
leading to a serum bicarbonate threshold of 17–19 mEq/L, 
below the recommended K/DOQI level of 22 mEq/L (De 
Santo et al 2006). There are abundant data from short-term 
metabolic studies in patients with CKD indicating that 
metabolic acidosis, a common condition in renal insufﬁ  -
ciency, may set up or worsen protein-energy malnutrition, 
inﬂ  ammation, and bone disease. Although carbonate is the 
alternate counterion to chloride on the polymer backbone 
of sevelamer, the active poly(allylamine) responsible for 
phosphate (PO4) binding remains unaltered between the two 
sevelamers. Therefore, it could be expected that sevelamer 
carbonate is acting similarly to sevelamer hydrochloride in 
serum P and lipid reduction, due to the fact that the anion 
does not play any role in phosphate binding. Together 
with dietary restriction and dialysis, sevelamer is currently 
prescribed in uremic HD patients to control hyperphospha-
temia. Sevelamer, either hydrochloride or carbonate, exerts 
its action via the reduction of the amount of bioavailable 
P generated from food intake and intestinally absorbed from 
gastrointestinal ﬂ  uids. In healthy patients, a poorly regulated 
P intestinal absorption is balanced by an efﬁ  cient urinary 
P excretion, thus warranting normophosphatemia, but when 
advanced renal failure develops, an inefﬁ  cient or absent 
P excretion no longer balances the unrelenting intestinal 
P absorption, thus leading to hyperphosphatemia. Looking 
at the clinical evidence produced with sevelamer carbonate 
to date, sevelamer carbonate has been demonstrated to be as 
effective as sevelamer hydrochloride in terms of serum P and 
serum lipid reduction in two different studies, one involv-
ing ESRD patients in hemodialysis and the other involving 
CKD, non-dialysis patients. A randomized, double blind, 
crossover design study was performed in HD patients to 
document the substantial equivalence of sevelamer carbonate 
with the hydrochloride form (Delmez et al 2007). Patients 
were eligible if they were on HD 3 times per week for at 
least 3 months. Ninety-two percent of the enrolled popula-
tion was maintained on sevelamer hydrochloride as the sole 
phosphate binder at a total daily dose of 13.6 g, with or 
without vitamin D analog and/or lipid lowering therapy, and 
patients were reported to be historically well controlled in 
terms of serum P (3.5–6.5 mg/dL). After a 5-week run-in 
period to titrate the dose of sevelamer hydrochloride, cina-
calcet, and vitamin D analog, 79 HD patients were randomly 
assigned in a 1:1 fashion to either sevelamer carbonate or 
sevelamer hydrochloride for 8 weeks followed by a crossover 
to the other treatment for additional 8 weeks. Sevelamer 
starting dose was individualized to the prescribed dose dur-
ing the run-in period. Three subgroups of patients could be 
roughly identiﬁ  ed on the basis of the daily dosage: (a) 4.8, 
(b)  4.8 to 9.6, and (c) 9.6 g/day. Unfortunately, the paper 
by Delmez et al (2007) did not report the individual serum 
P level, total cholesterol, LDL, and serum bicarbonate, or 
the average serum P level of the three subgrouped patients Therapeutics and Clinical Risk Management 2008:4(4) 824
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according to the need of a so strikingly different daily dosing, 
determined at the end of the 5-week run-in period. Patients 
were instructed to maintain the same daily dose throughout 
the full observational period, ie, 16 weeks. In the equivalence 
testing with a 90% CI for log-transformed serum P within the 
range of 0.80–1.25, the mean serum P was 4.6 ± 0.9 mg/dL 
during sevelamer carbonate treatment and 4.7 ± 0.9 mg/dL 
during sevelamer hydrochloride treatment. Efﬁ  cacy assess-
ment was run in the per protocol set (PPS), thus excluding 
protocol deviations expected to bias the results. Seventy-one 
percent of patients during sevelamer carbonate and 70% 
during sevelamer hydrochloride treatment were within the 
recommended serum P range. At the end of each treatment, 
41% of patients treated with sevelamer carbonate and 53% 
of patients treated with sevelamer hydrochloride had a serum 
bicarbonate level lower than the recommended value of 22 
mEq/L. These results suggest a better outcome in serum 
bicarbonate at the end of sevelamer carbonate treatment, 
whereas patients during sevelamer hydrochloride treatment 
presented with lower serum values of total cholesterol and 
LDL cholesterol, suggestive of a better outcome in lipid 
lowering proﬁ  le at the end of sevelamer hydrochloride treat-
ment compared with the carbonate.
It has to be mentioned that recently Qunibi et al (2008) 
showed that the reduction of low-density lipoprotein cho-
lesterol (LDL-C) levels may be responsible for the lowering 
of CAC in patients treated with sevelamer hydrochloride. 
Indeed, they showed that after intensive lowering of LDL-C 
levels for 1 year with atorvastatin, hemodialysis patients 
treated with either calcium acetate or sevelamer experienced 
similar progression of CAC (Qunibi et al 2008).
Sevelamer carbonate 
in hyperphosphatemic, non-dialysis 
patients
In a recent open label, single arm study, Ketteler et al (2008) 
administered sevelamer carbonate at a mean actual daily 
dosage of 5.5 g (6–7 sevelamer carbonate 800 mg tablets 
per day) to CKD patients with mean serum P  6.2 ± 0.8 
mg/dL and not under replacement therapy. A signiﬁ  cant 1.4 
mg/dL decrease in serum P was observed over an 8-week 
treatment, after a 2-week washout for patients previously on 
other phosphate binders, mainly calcium-based phosphate 
binders. Full recovery of serum P at baseline level was 
reached after the 2-week post-treatment washout period. 
By the end of sevelamer carbonate treatment, 75% of stage 
4 CKD patients (GFR 15–29 mL/min per 1.73 m2; 35% of 
study population) fell into the K/DOQI recommended 2.7 
and 4.6 mg/dL serum P range, and 70% of stage 5 CKD 
patients (GFR  15 mL/min per 1.73 m2; 65% of study   
population) had achieved a serum P level 5.5 mg/dL. 
A statistically signiﬁ  cant decrease in serum Ca × P product, 
total cholesterol, and serum LDL, and notably an increase 
in serum Ca and serum bicarbonate were also observed at 
the end of treatment.
Discussion
While exerting a lower control of hyperphosphatemia, 
sevelamer hydrochloride was demonstrated to worsen the 
metabolic acidosis compared with calcium carbonate, sig-
niﬁ  cantly decreasing the plasma bicarbonate concentrations 
to the threshold of 17 mEq/L and reducing the serum albumin 
levels over a 24-week treatment in HD patients (De Santo 
et al 2006). Metabolic acidosis has been reported to act as 
a uremic toxin, and the recommended K/DOQI predialysis 
bicarbonate concentration is 22 mEq/L. Forty-one percent 
of HD patients during sevelamer carbonate treatment, and 
53% during sevelamer hydrochloride treatment, were below 
the recommended K/DOQI threshold. The increase in serum 
bicarbonate observed with sevelamer carbonate may therefore 
confer an increased beneﬁ  t over sevelamer hydrochloride treat-
ment, which is acid-base neutral or potentially acidifying.
Acidosis has been associated with adverse effects on 
bone metabolism (Kraut 1995) and increased malnutri-
tion and inﬂ  ammation (Kalantar-Zadeh et al 2004) in HD 
patients. Oral bicarbonate supplementation was found to 
result in fewer hospital admissions and fewer days hos-
pitalized in peritoneal dialysis patients (Szeto et al 2003). 
Acidosis is commonly seen in patients with CKD, and these 
effects may be of more concern in the predialysis patients, 
for whom the dialysis modality itself is not being used to 
correct these abnormalities. For this reason, sevelamer 
carbonate’s manufacturer is proposing the product as pref-
erable option in CKD non-dialysis patients for phosphate-
binding therapy.
The need for phosphate-binding therapy in uremic 
patients is a cornerstone in patient management. When renal 
failure occurs and insigniﬁ  cant P renal excretion does not 
balance the unrelenting absorption of phosphate from gastro-
intestinal ﬂ  uids, the reduction of the amount of bioavailable 
phosphate generated by dietary intake remains the only way 
to reduce hyperphosphatemia. Sevelamers seem to present 
some advantages over other still largely prescribed phosphate 
binders, such as aluminium hydroxide and calcium-based 
binders, because of no systemic toxicity on the one hand and 
no additional calcium load on the other, this latter condition Therapeutics and Clinical Risk Management 2008:4(4) 825
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being particularly relevant when considering recent evidence 
of increased vascular calciﬁ  cation by calcium-based binders. 
Even if secondary analysis of the DCOR study showed that 
treatment with sevelamer compared with calcium-based bind-
ers was not correlated with a reduction of overall mortality, 
cause-speciﬁ  c mortality, morbidity, or ﬁ  rst or cause-speciﬁ  c 
hospitalization, the authors observed a beneﬁ  cial effect on 
multiple all-cause hospitalizations and hospital days, which 
are important because cost-analysis represents a major prob-
lem in treating dialysis patients.
Nevertheless, as can be inferred from the Delmez et al 
(2007) study on sevelamer carbonate in HD patients, compli-
ance with a daily dosage requiring up to 13.6 g remains a major 
problem, either for pharmacoeconomic affordability and for 
adherence to the multi-approach therapy, commonly prescribed 
to dialysis patients requiring a relevant daily pill burden. The 
better outcome of sevelamer carbonate on serum bicarbonate 
balance over a bioequivalent reduction of hyperphosphatemia 
compared with sevelamer hydrochloride is noteworthy. 
However, only approximately 50% of dialysis patients under 
sevelamer hydrochloride treatment achieve the recommended 
K/DOQI serum P level of 5.5 mg/dL. Based on its bioequiva-
lence to hydrochloride in the reduction of hyperphosphatemia, 
the same percentage of treatment success could be expected for 
sevelamer carbonate. Therefore, although nephrologists have 
several choices in phosphate-binding therapy, currently no gold 
standard seems to exist or to be preferably recommendable 
among commercially available competitors.
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